Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

The Lancet

Volumn 388, Issue 10062, 2016, Pages 2873-2884

  Gauthier, Serge ^a   Feldman, Howard H ^b   Schneider, Lon S ^c   Wilcock, Gordon K ^d   Frisoni, Giovanni B ^e   Hardlund, Jiri H ^f   Moebius, Hans J ^g   Bentham, Peter ^f   Kook, Karin A ^h   Wischik, Damon J ^f   Schelter, Bjoern O ⁱ   Davis, Charles S ^k   Staff, Roger T ^j   Bracoud, Luc ^l   Shamsi, Kohkan ^m   Storey, John M D ⁱ   Harrington, Charles R ^j   Wischik, Claude M ^f,j  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f TAURX THERAPEUTICS LTD   (United Kingdom)

^g Moebius Consult   (Switzerland)

^h Salamandra LLC   (United States)

ⁱ UNIVERSITY OF ABERDEEN   (United Kingdom)

^j UNIVERSITY OF ABERDEEN   (United Kingdom)

^k CSD Biostatistics   (United States)

^l BioClinica Inc   (United States)

^m RadMD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; LEUCO METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE; MEMANTINE; METHYLENE BLUE; NEUROLEPTIC AGENT; PROTEIN INHIBITOR; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ACTIVITY OF DAILY LIVING ASSESSMENT; ADVERSE OUTCOME; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE CO OPERATIVE STUDY ACTIVITIES OF DAILY LIVING INVENTORY SCALE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CONVULSION; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FECES COLOR; FEMALE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HUMAN; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; RANDOMIZED CONTROLLED TRIAL; SEROTONIN SYNDROME; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MOUSE; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS; TREATMENT FAILURE;

EID: 85003441308     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31275-2     Document Type: Article

References (30)

1. 1 Winblad, B, Amouyel, P, Andrieu, S, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol 15 (2016), 455–532.
2. 2 Prince, MJ, Wimo, A, Guerchet, MM, et al. World Alzheimer report 2015—the global impact of dementia: an analysis of prevalence, incidence, cost and trends, 2015, Alzheimer's Disease International, London.
3. 3 Mullane, K, Williams, M, Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?. Biochem Pharmacol 85 (2013), 289–305.
4. 4 Wischik, CM, Crowther, RA, Stewart, M, Roth, M, Subunit structure of paired helical filaments in Alzheimer's disease. J Cell Biol 100 (1985), 1905–1912.
5. 5 Wischik, CM, Novak, M, Edwards, PC, Klug, A, Tichelaar, W, Crowther, RA, Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85 (1988), 4884–4888.
6. 6 Wischik, CM, Novak, M, Thøgersen, HC, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc Natl Acad Sci USA 85 (1988), 4506–4510.
7. 7 Brier, MR, Gordon, B, Friedrichsen, K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Science Transl Med, 8, 2016, 338ra66.
8. 8 Maruyama, M, Shimada, H, Suhara, T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108.
9. 9 Wischik, CM, Harrington, CR, Storey, JMD, Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 88 (2014), 529–539.
10. 10 Braak, H, Del Tredici, K, The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 121 (2011), 171–181.
11. 12 Wischik, CM, Edwards, PC, Lai, RYK, Roth, M, Harrington, CR, Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93 (1996), 11213–11218.
12. 13 Harrington, CR, Storey, JMD, Clunas, S, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer's disease. J Biol Chem 290 (2015), 10862–10875.
13. 14 Baddeley, TC, McCaffrey, J, Storey, JMD, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J Pharmacol Exp Ther 352 (2015), 110–118.
14. 15 Melis, V, Magbagbeolu, M, Rickard, JE, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol 26 (2015), 353–368.
15. 16 Wischik, CM, Staff, RT, Wischik, DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimer's Dis 44 (2015), 705–720.
16. 17 Salloway, S, Sperling, R, Fox, NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
17. 18 Doody, RS, Thomas, RG, Farlow, M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 311–321.
18. 19 DiSanto, AR, Wagner, JG, Pharmacokinetics of highly ionized drugs. II. Methylene blue–absorption, metabolism, and excretion in man and dog after oral administration. J Pharmaceut Sci 61 (1972), 1086–1090.
19. 20 Posner, K, Brown, GK, Stanley, B, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168 (2011), 1266–1277.
20. 21 Alusik, S, Kalatova, D, Paluch, Z, Serotonin syndrome. Neuroendocrinol Lett 35 (2014), 265–273.
21. 22 Ramsay, RR, Dunford, C, Gillman, PK, Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 152 (2007), 946–951.
22. 23 Murray, AD, Staff, RT, Shenkin, SD, Deary, IJ, Starr, JM, Whalley, LJ, Brain white matter hyperintensities: relative importance of vascular risk factors in nondemented elderly people. Radiology 237 (2005), 251–257.
23. 24 Westfall, PH, Multiple testing of general contrasts using logical constraints and correlations. J Am Stat Assoc 92 (1997), 299–306.
24. 25 Frisoni, GB, Fox, NC, Jack, CR, Scheltens, P, Thompson, PM, The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6 (2010), 67–77.
25. 26 Nestor, SM, Rupsingh, R, Borrie, M, et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain 131 (2008), 2443–2454.
26. 27 Risacher, SL, McDonald, BC, Tallman, EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 73 (2016), 721–732.
27. 28 Inestrosa, NC, Alvarez, A, Pérez, CA, et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16 (1996), 881–891.
28. 29 Mohamed, LA, Keller, JN, Kaddoumi, A, Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model. Biochim Biophys Acta 1862 (2016), 778–787.
29. 30 Mohamed, LA, Qosa, H, Kaddoumi, A, Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats. ACS Chem Neurosci 6 (2015), 725–736.
30. 11 Lai, RYK, Harrington, CR, Wischik, CM, Absence of a role for phosphorylation in the tau pathology of Alzheimer's disease. Biomolecules, 6, 2016, 19.